Pharma’s $100 million West Coast battle

By Robert King

Published November 7, 2016 5:01am ET

Add Washington Examiner on Google

Pharma’s $100 million West Coast battle — Gilead Sciences, which got into hot water with Congress a few years ago after releasing a pricey hepatitis C cure, contributed $4 million to the campaign. (AP Photo) | Eric Risberg

The pharmaceutical industry has spent more than $100 million in a battle to defeat a California ballot measure that could put price caps on its products.

California voters go to the polls Tuesday to vote on Proposition 61, which would prohibit state medical programs from buying any drug that doesn’t have the same price as those obtained by the U.S. Department of Veterans Affairs.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

2016 Elections California Minusextra Pharmaceutical Industry Robert King Veterans Affairs